Eisai’s Lecanemab BLA Filing A Key Step For Ailing Biogen
Completed Rolling Submission Beats Lilly’s Donanemab To US FDA
Aduhelm commercialization was a bust, so Biogen’s next big hope for a potential blockbuster Alzheimer’s therapy is partner Eisai’s amyloid protofibril-targeting antibody lecanemab.
